PUBLISHER: The Business Research Company | PRODUCT CODE: 1946980
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946980
Point-of-care hematology diagnostics refer to medical tests conducted at or near the site of patient care to quickly evaluate blood-related conditions, such as anemia, infections, or clotting disorders. These tests deliver rapid and accurate hematological results to support timely clinical decisions, particularly in emergency or resource-limited settings. This approach minimizes the reliance on centralized laboratory testing and accelerates diagnosis and treatment.
The primary types of point-of-care hematology diagnostics include complete blood count (CBC), coagulation testing, hemoglobin testing, anemia diagnosis, and others. A CBC measures various blood components, including red blood cells, white blood cells, hemoglobin, hematocrit, and platelets, helping to assess overall health and detect a wide range of disorders. These diagnostics are available as consumables and systems and are offered in both prescription-based and over-the-counter formats, serving end users such as diagnostic centers, hospitals, blood banks, transfusion centers, and other healthcare facilities.
Tariffs are impacting the point of care hematology diagnostics market by increasing costs of imported diagnostic systems, reagents, and electronic components used in compact analyzers. Consumables and system segments are most affected, particularly in Asia-Pacific and Latin American regions that rely heavily on imported diagnostic devices. These cost pressures have influenced pricing and procurement decisions for hospitals and diagnostic centers. However, tariffs have also encouraged local manufacturing, regional sourcing of consumables, and innovation in cost-effective point of care diagnostic solutions.
The point of care hematology diagnostics market research report is one of a series of new reports from The Business Research Company that provides point of care hematology diagnostics market statistics, including point of care hematology diagnostics industry global market size, regional shares, competitors with a point of care hematology diagnostics market share, detailed point of care hematology diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point of care hematology diagnostics industry. This point of care hematology diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point of care hematology diagnostics market size has grown strongly in recent years. It will grow from $2.9 billion in 2025 to $3.16 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to dependence on centralized laboratory testing, increasing burden of anemia and blood disorders, growth in hospital emergency admissions, need for faster diagnostic turnaround, limited access to laboratory infrastructure in rural areas.
The point of care hematology diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising prevalence of chronic and infectious diseases, expansion of point of care testing programs, increasing demand for rapid diagnostics in emergency care, technological advancements in compact hematology analyzers, growth in decentralized healthcare delivery models. Major trends in the forecast period include rising adoption of rapid bedside blood testing, growing demand for decentralized diagnostics in emergency settings, increasing use of portable and handheld hematology devices, expansion of point of care testing in resource-limited areas, focus on faster turnaround time for clinical decision-making.
The increasing prevalence of blood disorders is expected to drive the growth of the point-of-care hematology diagnostics market in the coming years. Blood disorders are conditions that affect components of the blood, including red blood cells, white blood cells, platelets, or plasma. Their rising incidence is largely due to the growing prevalence of chronic diseases, which directly impact blood health and necessitate ongoing monitoring. Point-of-care hematology diagnostics facilitate timely detection and monitoring by delivering rapid, accurate results at or near the site of patient care, enabling faster clinical decisions and improved disease management. For example, in March 2025, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 22,010 individuals are expected to be diagnosed with acute myeloid leukemia (AML), predominantly in adults, with around 11,090 projected deaths. AML accounts for roughly one-third of adult leukemia cases and about 1% of all cancers. Consequently, the rising incidence of blood disorders is propelling the growth of the point-of-care hematology diagnostics market.
Key companies in this market are developing advanced solutions, such as cartridge-based AI-powered hematology analyzers, to deliver rapid and precise on-site blood analysis. These compact devices utilize single-use reagent cartridges and artificial intelligence algorithms to perform complete blood counts (CBC) and other analyses directly at the point of care. For instance, in September 2024, Zoetis Inc., a US-based veterinary health company, launched Vetscan OptiCell, a cartridge-based, AI-powered hematology analyzer for veterinary use. This system provides rapid, reference-quality CBC results within minutes, while minimizing maintenance and hands-on time. It features AI-driven image analysis and viscoelastic focusing technology to accurately align cells, classify blood cells, and automatically detect abnormalities, ensuring reliable and efficient diagnostics.
In June 2023, Mars Inc., a US-based pet company, acquired Heska Corporation for an undisclosed amount. This acquisition expands Mars' veterinary diagnostics capabilities and strengthens its position in advanced animal healthcare by leveraging Heska's point-of-care hematology and specialty diagnostic solutions. Heska Corporation is a US-based veterinary diagnostics company offering point-of-care (POC) hematology diagnostics.
Major companies operating in the point of care hematology diagnostics market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., BioMedomics Inc., PixCell Medical Technologies Ltd., Boule Diagnostics AB, Nihon Kohden Corporation, Edan Instruments Inc., A Menarini Industrie Farmaceutiche Srl, Becton Dickinson and Company, Ortho Clinical Diagnostics, Khema Diagnostics, Bio-Rad Laboratories Inc.
North America was the largest region in the point of care hematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care hematology diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the point of care hematology diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The point of care hematology diagnostics market consists of revenues earned by entities by providing services such as rapid blood testing, decentralized diagnostic solutions, and home-based blood monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The point of care hematology diagnostics market also includes sales of portable hematology analyzers, cartridges and test kits, lancets, and reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Point Of Care Hematology Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses point of care hematology diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for point of care hematology diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point of care hematology diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.